Plasma Proteome-Wide Mendelian Randomization Analysis Reveals Biomarkers and Therapeutic Targets for Different Stages of COVID-19
Table 1
Phenotype definition for the COVID-19 outcomes.
Phenotype
No. of cases
No. of controls
Description
Very severe confirmed respiratory COVID-19 (severe COVID-19)
13,769
1,072,442
Hospitalized laboratory confirmed SARS-CoV-2 infection (RNA and/or serology based), AND (death OR respiratory support (intubation, CPAP, BiPAP, CNP (continue external negative pressure), Optiflow/very high flow positive end expiratory pressure —AND hospitalization with COVID19 as primary reason for admission
Hospitalized COVID-19
32,519
2,062,805
Hospitalized laboratory confirmed SARS-CoV-2 infection (RNA and/or serology based) AND hospitalization due to COVID-19-related symptoms
SARS-CoV-2 infection
122,616
2,475,240
Individuals with laboratory confirmation of SARS-CoV-2 infection (RNA and/or serology based) OR I/ICD coding/physician confirmed COVID-19 OR self-reported COVID-19 positive (e.g., by questionnaire)
